JPS60123417A - Drug delivery member - Google Patents
Drug delivery memberInfo
- Publication number
- JPS60123417A JPS60123417A JP23178283A JP23178283A JPS60123417A JP S60123417 A JPS60123417 A JP S60123417A JP 23178283 A JP23178283 A JP 23178283A JP 23178283 A JP23178283 A JP 23178283A JP S60123417 A JPS60123417 A JP S60123417A
- Authority
- JP
- Japan
- Prior art keywords
- water
- drug
- skin
- drug administration
- meth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
【発明の詳細な説明】
本発明は経皮吸収性薬物を体内に投与するための薬物投
与部材に関するものであり、詳しくは皮膚面に直接貼付
し、局所性疾患又は全身性疾患の治療を目的として経皮
的に薬物を体内へ投与するための薬物投与部材に関する
ものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a drug administration member for administering transdermally absorbable drugs into the body, and more specifically, it is attached directly to the skin surface for the purpose of treating local or systemic diseases. The present invention relates to a drug administration member for transdermally administering drugs into the body.
従来、疾患治療を目的とした薬物の体内投与方法として
は、経口による投与、注射による直接投与が主流であっ
たが、肝臓による第一次代謝や、長時間に亘る有効血中
濃度の維持、大凧投与による副作用などの問題点から、
近年テープ製剤を皮膚面に貼着することによる薬物の経
皮投与が種々提案されている。これらのテープ製剤を構
成する基材物質としては、主に皮IN接陪性を有する天
然ゴム系9合成ゴム系、アクリル系の如き高分子物質が
使用されているが、薬理効果や皮膚刺激性。Conventionally, the main methods of administering drugs to the body for the purpose of disease treatment have been oral administration and direct administration by injection. Due to problems such as side effects caused by administering large kites,
In recent years, various proposals have been made for transdermal administration of drugs by applying tape preparations to the skin surface. As the base material constituting these tape preparations, polymeric substances such as natural rubber, 9 synthetic rubber, and acrylic, which have skin-in-adhesion properties, are mainly used, but they do not have pharmacological effects or skin irritation. .
薬物の分カイ抑1li(1などの而で未だ満足ゆくもの
が得られていないのが現状である。また、これらを解消
する目的で皮I’ll浸透剤、湿潤剤、酸化防止剤の如
き添加剤を併用しているが、皮層接着性の低下など新た
な問題点が生じ、望ましい結果が得られていない。The current situation is that a satisfactory product has not yet been obtained with drugs such as 1li (1).In addition, in order to solve these problems, skin penetration agents, humectants, antioxidants, etc. Although additives are used in combination, new problems such as a decrease in skin adhesion have arisen, and the desired results have not been obtained.
更に、池の基材物質として合成ゴム−鉱油などからなる
油性ゲル、アクリル酸ナトリウムやポリビニルアルコー
ルの如き水溶性高分子−水からなる水性ゲルを利用した
ものが提案されているが、前者のものは初期接着性は優
れるものの、性分などのg!8!湿性に劣るため長期の
皮膚接着性が劣り、皮膚への密着性不良のために治療に
充分な薬効を期持し難い。また後者のものは基材物質か
らの薬物放出は良好であるが、薄膜化した際の保型性、
皮膚接着性、薬物の溶解・分散性に難があり外科用テー
プなどの補助手段での固定が必要であった。Furthermore, as base materials for ponds, oil-based gels made of synthetic rubber and mineral oil, and water-based gels made of water and water-soluble polymers such as sodium acrylate or polyvinyl alcohol have been proposed. Although the initial adhesion is excellent, G! 8! Due to poor moisture properties, long-term skin adhesion is poor, and due to poor adhesion to the skin, it is difficult to maintain sufficient medicinal efficacy for treatment. In addition, the latter has good drug release from the base material, but has poor shape retention when made into a thin film.
Skin adhesion and drug solubility/dispersion were difficult, requiring fixation with auxiliary means such as surgical tape.
本発明者らは、これらの欠点を解消するために鋭意検討
を重ねた結果、天然ゴム、合成ゴム、アクリル系重合体
などの常温で粘着性を有し、且つ水不溶性の高分子物質
に特定の水溶性高分子物質及び経皮吸収性薬物を配合し
た薬物投与部材が、感圧性接着剤としての皮111接着
性、凝集性、保型性、薬物の分解抑制性(薬物安定性)
と、水溶性高分子物質による水性ゲル様の吸水性、皮I
#湿潤性、薬物放出性を兼備し、非常に優れ7と密着性
によって望ましい薬理効果が得られることを見い出し、
本発明に至ったものである。As a result of intensive studies to eliminate these drawbacks, the present inventors have identified polymeric substances that are sticky at room temperature and water-insoluble, such as natural rubber, synthetic rubber, and acrylic polymers. A drug administration member containing a water-soluble polymeric substance and a transdermal drug has excellent adhesion, cohesion, shape retention, and drug decomposition inhibiting properties (drug stability) as a pressure-sensitive adhesive.
and water-based gel-like water absorbency due to water-soluble polymeric substances, skin I
#We discovered that it has both wettability and drug release properties, and that desirable pharmacological effects can be obtained due to its excellent adhesion.
This led to the present invention.
即ち、本発明は実質的に透湿性を有しない担持体上に、
常温で粘着性を有する薬物含有の感圧性接着剤層を直接
的又は間接的に設けてなる部材において、該感圧性接着
剤層が常温で粘着性を有し且つ水不溶性の高分子物質と
、エチレン性不飽和二重結合を1個有する単量体からな
る水溶性高分子物質及び/又は多糖類と、経皮吸収性薬
物を必須成分として構成されていることを特徴とする薬
物投与部材を提供するものである。That is, in the present invention, on a carrier having substantially no moisture permeability,
A member directly or indirectly provided with a drug-containing pressure-sensitive adhesive layer that is sticky at room temperature, the pressure-sensitive adhesive layer comprising a water-insoluble polymer substance that is sticky at room temperature; A drug administration member comprising a water-soluble polymer substance and/or polysaccharide made of a monomer having one ethylenically unsaturated double bond and a transdermal absorbable drug as essential components. This is what we provide.
本発明に用いられる常温で粘着性を有し且つ水不溶性の
高分子物質は、本発明の薬物投与部材を疾患治療のため
に皮膚面へ直接的に貼付適用した際、薬物含有の感圧性
接着剤層に充分な皮膚接着性と密封包帯効果(いわゆる
ODT効果)を与え、更に薬物に応じてその拡散移動を
望ましい速度で可能とする基剤であり、例えばシリコー
ンゴム。The polymer substance used in the present invention, which is adhesive at room temperature and water-insoluble, is a pressure-sensitive adhesive containing a drug when the drug administration member of the present invention is applied directly to the skin surface for disease treatment. A base that provides the drug layer with sufficient skin adhesion and an occlusive bandage effect (the so-called ODT effect) and, depending on the drug, allows its diffusion at a desired rate, such as silicone rubber.
ポリイソプレンゴム、ポリブテンゴム、スチレン−ブタ
ジェンゴム、スチレンーイソブレンースチL/ンブロッ
ク共重合体ゴム、アクリルゴム、天然ゴムの如きゴム系
高分子物質、ポリビニルアルキルエーテル、酢酸ビニル
系重合体の如きビニル系高分子物質、(メタ)アクリル
酸アルキルエステルを主成分単量体としたポリ(メタ)
アクリレート系高分子物質、ポリアミド系高分子物質な
どが挙げられ、これらは水難溶性であってもよい。更に
これらの高分子物質は架橋剤による薬物の分解を排除す
る観点から未架橋タイプのものを使用することが望まし
い。上記高分子物質のうち、含有する薬物の分解に対す
る安定性や薬物投与部材の皮j−接着性を考慮すると、
特にポリ(メタ)アクリレート系高分子物質が好ましく
、高分子化か++J能で且つ常温で粘着性を付与出来る
単量体として、例えばアクリル酸エチルエステル、(メ
タ)アクリル酸ブチルエステル、(メタ)アクリル酸ペ
ンチルエステル、(メタ)アクリル酸ヘキシルエステル
、(メタ)アクリル酸ヘプチルエステル、(メタ)アク
リル酸オクチルエステル、(メタ)アクリル酸/ニルエ
ステル、(メタ)アクリル酸デシルエステル、(メタ)
アクリル酸ドデシルエステル、(メタ)アクリル酸トリ
デシルエステルなしてもよいものである。また上記単量
体と共重合可能で凝集性及び皮膚接着性を向上させ、且
つ水溶性高分子物質又は多糖類との相溶性を高める目的
で、(メタ)アクリル酸、イタコン酸、マレイン酸、無
水マレイン師、クロトン酸、(メタ)アクリル酸2−ヒ
ドロキシエチルエステル、(メタ)アクリル酸2−ヒド
ロキシプロピルエステル。Rubber-based polymers such as polyisoprene rubber, polybutene rubber, styrene-butadiene rubber, styrene-isobrene-styrene block copolymer rubber, acrylic rubber, natural rubber, polyvinyl alkyl ether, vinyl acetate polymers, etc. Vinyl polymer material, poly(meth) whose main monomer is (meth)acrylic acid alkyl ester
Examples include acrylate polymer substances, polyamide polymer substances, and the like, and these may be poorly soluble in water. Furthermore, it is desirable to use non-crosslinked polymeric substances from the viewpoint of eliminating decomposition of the drug by the crosslinking agent. Among the above-mentioned polymeric substances, considering the stability of the contained drug against decomposition and the skin adhesion of the drug administration member,
Particularly preferred are poly(meth)acrylate-based polymers, and examples of monomers that can be polymerized and impart tackiness at room temperature include ethyl acrylate, butyl (meth)acrylate, and (meth)acrylate. Acrylic acid pentyl ester, (meth)acrylic acid hexyl ester, (meth)acrylic acid heptyl ester, (meth)acrylic acid octyl ester, (meth)acrylic acid/nyl ester, (meth)acrylic acid decyl ester, (meth)acrylic acid decyl ester
Acrylic acid dodecyl ester and (meth)acrylic acid tridecyl ester may also be used. In addition, for the purpose of copolymerizing with the above monomers and improving cohesion and skin adhesion, and increasing compatibility with water-soluble polymeric substances or polysaccharides, (meth)acrylic acid, itaconic acid, maleic acid, Maleic anhydride, crotonic acid, (meth)acrylic acid 2-hydroxyethyl ester, (meth)acrylic acid 2-hydroxypropyl ester.
アクリロニトリルの如き官能性単量体や、酢酸ビニル、
プロピオン酸ビニルの如きビニル系単量体を共重合する
ことも出来る。Functional monomers such as acrylonitrile, vinyl acetate,
It is also possible to copolymerize vinyl monomers such as vinyl propionate.
前記高分子物質は常温で粘着性を・aするものが選ばれ
るが、ガラス転移温度は−70〜−1O℃、好ましくは
−55〜−25°Cのものを使用することが出来1.+
;6分子・物vt単独でこれらのガラス転移湛度柁囲に
含まれないものは通常用いられている軟化剤の如き液状
添加剤などを配合してもよい。また該高分子物質の添加
量は薬物含有の感圧性接着剤層中に6()〜98重盾%
の範囲になるように61匈整するのが望ましく、60重
Mk%以下では以下に述べる水溶性高分子物質又は多糖
類との相溶性が悪くなり均一な感圧性接着剤層が得られ
醜く、史に個用皮ハ階曲への1ilJ期接着性が劣る傾
向を示す。また9 8 jR、i・(%以」二では水1
イ性高分子物質又は多糖類の添加1挟が少なくなるため
に吸水性、皮ff4湿潤性などの効311か期待出来な
い恐れが生じ°る。The polymer material is selected to have adhesiveness at room temperature, and those having a glass transition temperature of -70 to -10°C, preferably -55 to -25°C can be used.1. +
;6 Molecules/substances vt alone that are not included in these glass transition ranges may be mixed with commonly used liquid additives such as softeners. The amount of the polymeric substance added is 6() to 98% in the drug-containing pressure-sensitive adhesive layer.
It is desirable to adjust the pressure-sensitive adhesive layer to 61% so that it is in the range of Historically, individual skin tends to have poor adhesion to curved surfaces. Also, in 9 8 jR, i・(% or more), water 1
Since the amount of added polymeric substances or polysaccharides is reduced, there is a possibility that the effects such as water absorption and skin wettability cannot be expected.
本発明にて用いられるエチレン性不飽和二重結合を1個
・fjする?1(量体からなる水溶性高分子物質及び/
又は多糖類は、薬物さ有の感圧性接層剤層に品い水親和
性を付与し、本つd明の薬物投与部材を皮膚に貼着した
際に湿分を吸収して皮jΔ湿潤性を高め且つ皮1f/1
]着性を高める作用をするものであり、例えばポリビニ
ルアルコール、変性ポリビニルアル:l−ル、ポリ(メ
タ)アクリルは、ポリ(メタ)アクリル版ナトリウム、
ビニルメチルニー テzk −無水マレイン酸共重合体
の如きエチレン性不飽和二重結合を1個有する単量体か
らなる水溶性高分子物質、カルボキシメチルセルロース
。One ethylenically unsaturated double bond used in the present invention, fj? 1 (a water-soluble polymeric substance consisting of
Alternatively, the polysaccharide imparts water affinity to the pressure-sensitive adhesive layer containing the drug, and when the drug administration member of the present invention is applied to the skin, it absorbs moisture and moisturizes the skin. Increases sex and skin 1f/1
] For example, polyvinyl alcohol, modified polyvinyl alcohol, poly(meth)acrylic, sodium poly(meth)acrylic,
Carboxymethyl cellulose is a water-soluble polymeric substance consisting of a monomer having one ethylenically unsaturated double bond, such as a vinyl methyl nitride-maleic anhydride copolymer.
ヒドロキシエチルセル四−ス、ヒドロギシプロビルセノ
[ロース、メチルセルロース、デンプン、プルラン、寒
天、デキストリンの如き授糖類などを挙り“る仁とが出
来、これらは少なくとも一拙添加される。また上記水浴
性高分子物質及び/又は多糖類の添加量は、薬物台イj
のlU圧圧接接着剤層中2〜40爪墓%、好ましくは5
〜20重赦%の範囲で添加するのかよく、これらが粉末
状などの固整状急のものは粒径を300μm以下の粉体
に粉砕したのち、そのまま或いは水やアルコール類の如
き溶媒に浴IMシた浴液状態で添加混合する。Saccharides such as hydroxyethyl cellulose, hydroxyprovirceno[loose, methyl cellulose, starch, pullulan, agar, dextrin, etc.] can be added, and at least one of these may be added. The amount of water-based polymeric substances and/or polysaccharides added depends on the drug level.
2 to 40%, preferably 5% in the lU pressure bonding adhesive layer
It is best to add it in a range of ~20% by weight. If these are in a powdered form or other hard-formed form, grind them to a powder with a particle size of 300 μm or less, and then add them as they are or by soaking them in a solvent such as water or alcohol. Add and mix in the IM bath liquid state.
本発明において使用される経皮吸収性薬物は、薬物投与
部材を皮IP1面上に貼付通用した際に該薬物が経皮的
に体内に吸収されるものであれば特に制限はなく、例え
ば
イ)コルチコステロイド類:例えばハイドロコーチゾン
、プレドニゾロン、ベクロメタゾンプロヒ゛オネート、
フルメタシン、トリアムシノロン、トリアムシノロンア
セトニド、フルオシノロン、フルオシノロンアセトニド
、フルオシ/ロンアセトニドアセテート、プロピオンl
?クロベタゾールなど、
口)、!1痛消炎剤:例えばアセトアミノフェン、メフ
ェナム酸、フルフェナム師、インドメタシン。The transdermal absorbable drug used in the present invention is not particularly limited as long as the drug is absorbed transdermally into the body when the drug administration member is pasted on the skin IP1 surface. ) Corticosteroids: e.g. hydrocortisone, prednisolone, beclomethasone proionate,
flumethacin, triamcinolone, triamcinolone acetonide, fluocinolone, fluocinolone acetonide, fluocinolone acetonide acetate, propion
? Clobetasol, etc., mouth),! 1. Anti-inflammatory drugs: eg acetaminophen, mefenamic acid, flufenamic acid, indomethacin.
ジクロフェナック、ジクロ7エナツクナトリウム。Diclofenac, Diclofenac Sodium.
アルクロフェナック、オキシフェンブタシン、フェニル
ブタシン、イブプロ7エ/。Alclofenac, oxyphenbutacin, phenylbutacin, ibupro7e/.
フェン、サリチル酸、サリチ/I/mメチル、l−メン
トール、カンファー、スリンダック、トルメチンナトリ
ウム、ナプロキセン、フェンブフェンなど、
ハ) WtJ眠gVfrM : 例えば7エ/バルビタ
ール、アモパルビタール、シクロバルビタール、ロラゼ
ノぐム、ハロペリドールなど、
二)′a神安定剤:例えばフルフェナジン、テオリダジ
ン、ジーrゼパム、フルニトラゼパム、クロルプロマジ
ンなど、
ホ)抗高血圧剤:例えばクロニジン9塩酸クロニジン、
ピント廿−ル、プロプラノロール、fLuMプロプラノ
ロール、プフラノール、インデノロール。Phen, salicylic acid, salicylic acid/I/m-methyl, l-menthol, camphor, sulindac, tolmetin sodium, naproxen, fenbufen, etc. c) WtJ sleep gVfrM: For example, 7e/barbital, amoparbital, cyclobarbital, lorazenogum, haloperidol etc., 2) 'A tranquilizers: e.g. fluphenazine, theoridazine, dirzepam, flunitrazepam, chlorpromazine, etc. e) antihypertensive agents: e.g. clonidine 9-hydrochloride,
Pintorol, propranolol, fLuM propranolol, pufranol, indenolol.
ブクモロール、ニフェジピンなど、 へ)降圧利尿剤:例えばハイドロサイアザイド。Bucumolol, nifedipine, etc. f) Antihypertensive diuretics: e.g. hydrothiazide.
ベンドロフルナサイアザイド、シクロペンチアザイドな
ど、
ト)抗生物質:例えばペニシリン、テトラサイクリン、
オキシテトラサイクリン、硫酸フラジオマインン、エリ
スロマイシン、クロラムフエニフールなど、
チ)麻酔剤:例えばリドカイン、ベンシカイン。Bendrofluna thiazide, cyclopenthiazide, etc. g) Antibiotics: e.g. penicillin, tetracycline,
Oxytetracycline, fradiomain sulfate, erythromycin, chloramphenifur, etc.; 1) Anesthetics: e.g. lidocaine, benzicaine.
アミノ安息香酸エチルなど、 リ)抗菌性物質1例えは塩化ベンザルコニウム。Ethyl aminobenzoate, etc. li) An example of an antibacterial substance is benzalkonium chloride.
ニトロフラゾン、ナイスタチン、アセトスルファミン、
クロトリマゾールなど、
ヌ)抗真菌物質:例えばペンタマイシン、アムホテリシ
ンB、ピロールニドリン、クロトリマゾールなど、
ル)ビタミン剤;例えばビタミンA、エルゴカルシフェ
ロール、コレカルシフ、ロール、オクトチアジン、リボ
フラビン酪酸エステルなど、ヲ)抗てんかん剤:例えば
ニトラゼ/ぐム、メプロバメート、クロナゼパムなど、
ワ)冠皿り4・拡張/′1lJ=例えばニトログリセリ
ン、ニトロクリコール、イソソルビドジナイトレート。Nitrofurazone, nystatin, acetosulfamine,
clotrimazole, etc. n) Antifungal substances: e.g. pentamycin, amphotericin B, pyrrolnidoline, clotrimazole, etc. l) Vitamin preparations: e.g. vitamin A, ergocalciferol, cholecalcif, roll, octothiazine, riboflavin butyrate, etc. , w) Anti-epileptic drugs: e.g. nitraze/gum, meprobamate, clonazepam, etc. w) Crown plate 4/'1lJ = e.g. nitroglycerin, nitrocricol, isosorbide dinitrate.
エリスリトールテトラナイトレート、ペンタエリスリト
ールテトラナイトレート、プロパチルナイトレートなど
、
力)抗ヒスタミン剤:たとえば塩酸ジフェンヒドラミン
、クロルフ、ニラミン、ジフェニルイミダゾールなど、
ヨ)(L1咳剤:例えばデキストロメトルファン、チル
ブタミン、エフェドリン、塩酸エフェドリンなど、
り)性ホルモン:例えばプロゲステロン、エストラジオ
ールなど、
し)抗儒剤:例えばドキセピンなど、
ン)その他:例えば5−フルオロウラシル、ジヒドロエ
ルゴタミン、7エンタニール、テスモフレシン、ジゴキ
シン、メトクロブラシド、ドンペ1ノド、スフボラミン
、臭化水素酸スコポラミンナト、が挙げられ、これらの
薬物は必要に応じて2種類以上併用することが出来る。Erythritol tetranitrate, pentaerythritol tetranitrate, propyl nitrate, etc.) Antihistamines: For example, diphenhydramine hydrochloride, Chlorf, Niramine, diphenylimidazole, etc. (L1 cough medicines: For example, dextromethorphan, tilbutamine, ephedrine, hydrochloric acid) ephedrine, etc. ii) Sex hormones: e.g. progesterone, estradiol, etc. ii) Anti-Confucian agents: e.g. doxepin, etc. N) Others: e.g. 5-fluorouracil, dihydroergotamine, 7-entanyl, tesmofrecin, digoxin, metoclobraside, dope-1-nod, sufboramine , scopolamine hydrobromide, and two or more of these drugs can be used in combination as necessary.
上記薬物の添加液は目的とする治療及び/又は投与効果
によって異なるが、常温で粘着性を有し、且つ水不溶性
の高分子物質100重量部に対して約0.01〜20重
量部の範囲で含有される。The additive solution for the above drug varies depending on the intended treatment and/or administration effect, but is in the range of approximately 0.01 to 20 parts by weight per 100 parts by weight of a water-insoluble polymer substance that is sticky at room temperature. Contained in
前記成分からなる薬物含有の感圧性接着剤層を直接的又
は下塗り材料などを介して間接的に担持する相持体とし
ては、例えば各種プラスチックフィルム、紙類、不織布
、織布、金属箔、又はこれらとプラスチックフィルムと
の積層フィルムなどが挙げられるか、本発明の薬物投与
部材を皮膚面に貼着して薬物の経皮吸収による疾患治療
を行なうに際し、適用皮膚面の角質層のイ泉水量を高め
経皮吸収性を向」ニさせるために上記相持体は実質的に
透湿性を有しないものを選択、あるいは組み合わせるこ
とによっていわゆるODT効来が得られるようにするこ
とが必要である。Examples of carriers that support the drug-containing pressure-sensitive adhesive layer made of the above components directly or indirectly through an undercoating material include various plastic films, papers, nonwoven fabrics, woven fabrics, metal foils, and the like. When applying the drug administration member of the present invention to the skin surface to treat diseases through transdermal absorption of drugs, the amount of spring water in the stratum corneum on the skin surface to which it is applied can be reduced. In order to enhance transdermal absorption, it is necessary to select or combine carriers that do not have substantially moisture permeability, so that the so-called ODT effect can be obtained.
さらに本発明の薬物投与部材から効率よく薬物を放出さ
せるための経皮吸収補助物質として、例、tばブ0ピレ
ングリコール、ジエチレングリコール、ポリエチレング
リコール、ポリプロピレングリコールの如キグリコール
類、エチルアルコール、サリヂル師、尿素、アラントイ
ン、ジメチルスルホキシド、ジメチルアセトアミド、ジ
メチルホルムアミド、ジイソプロピルアジペート、ジエ
チルセバケート、エチルラウレート、ラノリン、鉱油、
各種界面活性剤の如き物質を必要に応じて一41Ilt
txi以上添加することが出来る。添加皇は皮膚接着
力及び凝集力とのバランスを考慮して、水不溶性の高分
子物fejj 100重坦部に対して0.5〜20重量
部の範囲が望ましい。Furthermore, transdermal absorption auxiliary substances for efficient drug release from the drug administration member of the present invention include, for example, glycols such as pyrene glycol, diethylene glycol, polyethylene glycol, and polypropylene glycol, ethyl alcohol, and salidil. , urea, allantoin, dimethyl sulfoxide, dimethyl acetamide, dimethyl formamide, diisopropyl adipate, diethyl sebacate, ethyl laurate, lanolin, mineral oil,
Substances such as various surfactants may be added as necessary.
It is possible to add more than txi. In consideration of the balance between skin adhesion and cohesive force, the additive amount is desirably in the range of 0.5 to 20 parts by weight per 100 parts by weight of the water-insoluble polymer.
前記必須成分から構成される薬物含有の感圧性接着剤層
は、実質的に水分を含まない形態で製剤化され薬物投与
部材を皮膚面に貼付後、皮膚面から分泌される湿分を吸
収して画期的なl$f徴を有するものであるので該投与
部材の保存はアルミニウム包装などの密封包装が好まし
い。The drug-containing pressure-sensitive adhesive layer composed of the above-mentioned essential components is formulated in a form that does not contain substantially water, and after the drug administration member is applied to the skin surface, it absorbs moisture secreted from the skin surface. Since the dispensing member has an epoch-making l$f characteristic, it is preferable to store the dispensing member in sealed packaging such as aluminum packaging.
以上に示したように本発明の薬物投与部材は身体の皮膚
面に直接貼り付けることにより含有する経皮吸収性薬物
を体内へ連続的に供給させ、局所性又は全身性疾患の治
療を持続的、且つ有効に行なうことが出来るという効果
を奏する。狛に必須成分であるエチレン性不飽和二重結
合を1個有する単社体からなる水溶性高分子物質及び/
又は多糖類は感圧性接着剤層に水性ゲル的特徴、即ち吸
水性、皮膚湿潤性、薬物放出性を付与し、更に皮膚から
分泌される湿分の吸水作用によってM hイ又は膨潤し
て該接着剤層を可塑化し皮I#面に対する密着性を向上
させ、優れた薬理効果を発揮する機能を付与する。また
通常のアクリル糸皮膚貼イ」部杓は剥離後、該部材の接
着面が油成分や垢などで〆り染されて11多貼付は困難
であったが、本発明の薬物投与部材によれば、薬物投与
部材を貼治後、吸水作用によって水性ゲル的性質を有す
るために粘着性が向上しく)1貼付が可能であり、a有
する薬物を無駄なく有効に使用することが出来る。As described above, the drug administration member of the present invention can be applied directly to the skin surface of the body to continuously supply the transdermal absorbable drug contained therein into the body, thereby providing continuous treatment for local or systemic diseases. , and can be carried out effectively. A water-soluble polymeric substance consisting of a single substance having one ethylenically unsaturated double bond, which is an essential component of Koma, and/
Alternatively, the polysaccharide imparts aqueous gel characteristics to the pressure-sensitive adhesive layer, that is, water absorption, skin wettability, and drug release properties, and furthermore, it swells and swells due to the water absorption effect of moisture secreted from the skin. The adhesive layer is plasticized to improve its adhesion to the skin I# surface, giving it the ability to exhibit excellent pharmacological effects. In addition, with the conventional acrylic thread skin patch ladle, the adhesive surface of the member is stained with oil components and dirt after peeling off, making it difficult to apply multiple patches, but with the drug administration member of the present invention, For example, after the drug administration member is pasted, it has water-absorbing properties and has aqueous gel-like properties, which improves its tackiness, making it possible to apply the drug once (a), making it possible to use the drug effectively without wasting it.
以Fに本発明の実施例を示し、更に具体的に説明するが
、本発明はこれらに限定されるものではなく、技術的思
想を逸脱しない範囲において釉々の1心用が可能である
。なお実施例中で部とあるのは重IK ffl!を示す
。Hereinafter, examples of the present invention will be shown and explained in more detail, but the present invention is not limited to these examples, and various types of glazes can be used without departing from the technical idea. In addition, in the examples, parts are heavy IK ffl! shows.
実施例1
−rクリル酸2−エチルヘキシルエステル96部、アク
リル酸4部、酢酸エチル42.9部、アゾビスイソブチ
ロニトリル0.2部を不活性ガス雰囲気下において四つ
目フラスコ内に仕込み、内温温度を60〜62℃で撹拌
してIR合反応を開始させ、反応希釈浴剤の酢酸エチル
190.4部を滴下して反応を制御しつつ8時間型合さ
せ、更に75〜80°Cに内温温度をη′濡して3時間
熟成し、ホ合率99.3%、30°Cにおける固形分3
0重量%での溶液粘度230ボイズの高分子物質溶液を
得た。Example 1 -r 96 parts of 2-ethylhexyl acrylate, 4 parts of acrylic acid, 42.9 parts of ethyl acetate, and 0.2 parts of azobisisobutyronitrile were charged into a fourth flask under an inert gas atmosphere. , the internal temperature was stirred at 60 to 62°C to start the IR combination reaction, 190.4 parts of ethyl acetate as a reaction diluting bath agent was added dropwise, and the molds were combined for 8 hours while controlling the reaction, and the mixture was further heated to 75 to 80°C. The internal temperature was kept at η' and aged for 3 hours.
A polymer substance solution having a solution viscosity of 230 voids at 0% by weight was obtained.
次に該高分子物質溶液の固形分95部に対して0.2部
のプロピオン酸クロベタゾールを添加混合し、充分に溶
解させたのち、粒径5〜10μBに粉砕したポリアクリ
ル酸ナトリウム4.81%ヲ加え、ホモミキサーにて均
一に分散させ、60μ扉厚のポリエチレンフィルム上に
乾燥後の厚みが50μmとなるように塗布し、80°C
で7分間乾燥して薬物投与部材を得た。Next, 0.2 parts of clobetasol propionate was added and mixed to 95 parts of the solid content of the polymer substance solution, and after sufficiently dissolving, 4.81 parts of sodium polyacrylate was ground to a particle size of 5 to 10 μB. %, dispersed uniformly with a homomixer, applied on a polyethylene film with a door thickness of 60 μm so that the thickness after drying was 50 μm, and heated at 80°C.
The mixture was dried for 7 minutes to obtain a drug administration member.
実施例2
トルエン溶液のシリコーン系粘着剤(商品名KRIOI
−101信越化学社製)の固形分85部に対して3部の
ロラゼパムを溶解させたアセトン溶液10部を添加混合
し、充分に溶解させたのち、粒径10〜20μmに粉砕
したポリビニルアルコール(ケン化度98%)12部を
加え、ホモミキサーにて均一に分散させ、80μ寡厚の
テフロンフィルム上に乾燥後の厚みが50μ扉となるよ
うに塗布し、80°Cで7分間乾燥して常温で粘着性を
有する薬物3イjのIiq>i圧性接オ′7剤層を形成
さ−V180μ寡厚のボリエつ川−ン/エチレンー酢1
賀ビニル共重合体の積層フィルムに転造して薬物投与部
材を得た。Example 2 Silicone adhesive in toluene solution (trade name: KRIOI)
10 parts of an acetone solution in which 3 parts of lorazepam was dissolved were added and mixed to 85 parts of solid content of 101 (manufactured by Shin-Etsu Chemical Co., Ltd.), and after sufficiently dissolving, polyvinyl alcohol ( Add 12 parts of saponification degree 98%), disperse uniformly with a homomixer, apply on a thin 80μ thick Teflon film so that the thickness after drying is 50μ, and dry at 80°C for 7 minutes. to form a pressure adhesive layer of drug 3 which is sticky at room temperature.
A drug administration member was obtained by rolling a laminated film of vinyl copolymer.
実施例3
スヂレンー・〔ソブレンースチレンブロソク共本合体ゴ
ム(イソプレン含量約86重足%)25部、Mlパラフ
ィン40部、ラノリン3部、脂肪族系石油イ1d脂(融
点100°C)20部をトルエン/酢酸エチル混イ1溶
剤(重量比1/2)65部にて充分に溶解、混合し高分
子物質溶液を得た。Example 3 25 parts of styrene-[styrene-styrene brosoxylic composite rubber (isoprene content: about 86% by weight), 40 parts of Ml paraffin, 3 parts of lanolin, aliphatic petroleum oil (melting point 100°C) 20 parts were sufficiently dissolved and mixed in 65 parts of toluene/ethyl acetate mixed solvent (weight ratio 1/2) to obtain a polymer substance solution.
次に該高分子物質溶液の固形分88部にクロニジン5部
を添加混合し充分に溶解はせたのち、ヒトiffギシプ
ロピルセルロース7部をmt7水15g[(に溶解させ
た水浴液を添加し、ホモミキサーにて均一に分R’(d
せ、50μ寡厚のポリプロピレンフィルン\上に乾]栗
後の厚みが50μ扉となるように塗布し、90 ”Cで
7分間乾燥して薬物投与部材を得た。Next, 5 parts of clonidine was added and mixed to 88 parts of the solid content of the polymer substance solution, and after sufficiently dissolving, 7 parts of human IF gicipropyl cellulose was added to 15 g of mt7 water [a water bath solution dissolved in , evenly in a homomixer in minutes R'(d
The mixture was coated onto a polypropylene film with a thin thickness of 50 μm to a thickness of 50 μm, and dried at 90”C for 7 minutes to obtain a drug administration member.
比較例1〜3
比較例1〜3は′88部1〜3に対応しており、各実施
例からポリアクリル酸ナトリウム、ポリビニルアルコー
ル、ヒドロキシプロピルセルロースを除いた以外は各実
施例と同様の操作を行ない、水溶性高分子物質又は多糖
類を含まない薬物投与部材を得た。Comparative Examples 1 to 3 Comparative Examples 1 to 3 correspond to '88 Parts 1 to 3, and were carried out in the same manner as in each Example except that sodium polyacrylate, polyvinyl alcohol, and hydroxypropyl cellulose were removed from each Example. A drug administration member containing no water-soluble polymeric substance or polysaccharide was obtained.
各実施例及び比較例にて得られた薬物投与部Hの特性結
果を第1表に示した。Table 1 shows the characteristics of drug administration area H obtained in each Example and Comparative Example.
第1表 第1表中の各特性の測定方法は以下の通りである。Table 1 The measurement method for each characteristic in Table 1 is as follows.
〔吸水率〕:各試料片(4×4α角)を25°Cの水中
に浸漬し、30分後の重hL増加分を浸漬前の重置にて
除し算出した。[Water absorption rate]: Each sample piece (4 x 4 α angle) was immersed in water at 25°C, and calculated by dividing the increase in weight hL after 30 minutes by the overlapping value before immersion.
〔水中放出率〕:各試料片(4X4Crn角)を30°
Cの水200 ratに浸漬、振盪し、1時間後、6時
間後に水lWtヲザンブリングしてその薬物の含有液を
高速液体クロマトグラフ−(UV検出)により測定し、
初期薬物含有mを100%とした時の放出率をめた。[Water release rate]: Each sample piece (4X4Crn angle) was held at 30°
It was immersed in 200 ml of water and shaken, and after 1 and 6 hours, it was mixed with water and the drug content was measured by high performance liquid chromatography (UV detection).
The release rate was calculated when the initial drug content m was set as 100%.
〔血中濃度〕:各試料片(3CInφ)をあらかじめ除
毛したラットの腹部に貼付し、8時間後ラットの血液を
抜き取り、ガスクロマトダラフィー装置を用いて薬物の
血中濃度を測定した。[Blood concentration]: Each sample piece (3CInφ) was pasted on the abdomen of a rat whose hair had been removed in advance, and after 8 hours, blood was drawn from the rat and the blood concentration of the drug was measured using a gas chromatograph.
〔移行率〕:各試料片(3CIRφ)をあらかじめ除毛
したラットの腹部に貼付し、8時間後者試料片を除去し
て残存する桑物量を測定し、初期薬物含有量を100%
とした時の皮j−移行率をめた。[Transfer rate]: Each sample piece (3CIRφ) was pasted on the abdomen of a rat whose hair had been removed in advance, and the latter sample piece was removed for 8 hours to measure the amount of remaining mulberry, and the initial drug content was 100%.
The skin j-transfer rate was calculated.
〔古貼伺性〕:各試料片(4X4aR角)を上腕部内側
に24時間貼付したのち除去し、再び同じ試料片を24
時間貼(=J’ した時の皮1帽への接着状態を目視に
て判別し、充分に接着しているものを○、端末ハガレを
生じたり、途中で脱落するものを△、全く再貼付出来な
いものを×とした。[Paperability]: Each sample piece (4x4aR square) was attached to the inside of the upper arm for 24 hours, then removed, and the same sample piece was attached again for 24 hours.
Visually judge the state of adhesion to the leather 1 hat when pasting (= J'), and if it is fully adhered, ○, if the end peels off or falls off during the process, △, or completely reapplied. Items that cannot be done are marked as ×.
第1表から明らかな如く、本発明の薬物投与部材は皮膚
接層性が良好で、吸水率が比較的晶く、水中放出率、血
中濃度、移行率のいずれも高いものであるので治療に対
して充分な効果を発揮するものである。As is clear from Table 1, the drug administration member of the present invention has good skin contact, relatively crystalline water absorption, and high water release rate, blood concentration, and migration rate, so it is suitable for treatment. It is fully effective against.
持許出願人 日東電気工業株式会社 代表者 土 方 三 部Permit applicant Nitto Electric Industry Co., Ltd. Representative: 3rd Department
Claims (4)
着性を有する薬物含有の感圧性接着剤層を直接的又は間
接的に設けてなる部材において、該感圧性接着剤層が常
温で粘着性を有し且つ水不溶性の高分子物質と、エチレ
ン性不飽和二重結合を1個有する単量体からなる水溶性
高分子物質及び/又は多糖類と、経皮吸収性薬物を必須
成分として構成されていることを特徴ともる薬物投与部
材。(1) A member in which a drug-containing pressure-sensitive adhesive layer that is sticky at room temperature is provided directly or indirectly on a carrier having substantially no moisture permeability, wherein the pressure-sensitive adhesive layer is A water-insoluble polymer substance that is sticky at room temperature, a water-soluble polymer substance and/or polysaccharide made of a monomer having one ethylenically unsaturated double bond, and a transdermal drug. A drug administration member comprising an essential component.
ガラス転移温度−70〜−1O°Cを有する未架橋物質
である特許請求の範囲第1項記載の薬物投与部材。(2) The drug administration member according to claim 1, wherein the water-insoluble polymeric substance that is sticky at room temperature is an uncrosslinked substance having a glass transition temperature of -70 to -10°C.
らなる水浴性高分子物質かポリビニルアルコール、変性
ポリビニルアルコール、ポリ(メタ)アクリル酸、ポリ
(メタ)アクリル師ナトリウム、ビニルメチルエーテル
−無水マレイン酸共重合体の群から選ばれた少なくとも
一種である特n’ 請求の範囲第1項記載の薬物投与部
材。(3) Water bathable polymeric substances consisting of monomers having one ethylenically unsaturated double bond, polyvinyl alcohol, modified polyvinyl alcohol, poly(meth)acrylic acid, sodium poly(meth)acrylic acid, vinyl methyl ether - At least one member selected from the group of maleic anhydride copolymers. The drug administration member according to claim 1.
プルラン、寒天、デキストリンの群から選ばれた少なく
とも一種である特許請求の範囲第1項記載の薬物投与部
材。(4) The polysaccharide is a cellulose ether derivative, starch,
The drug administration member according to claim 1, which is at least one member selected from the group of pullulan, agar, and dextrin.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23178283A JPS60123417A (en) | 1983-12-07 | 1983-12-07 | Drug delivery member |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23178283A JPS60123417A (en) | 1983-12-07 | 1983-12-07 | Drug delivery member |
Publications (1)
Publication Number | Publication Date |
---|---|
JPS60123417A true JPS60123417A (en) | 1985-07-02 |
Family
ID=16928943
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP23178283A Pending JPS60123417A (en) | 1983-12-07 | 1983-12-07 | Drug delivery member |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS60123417A (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02115119A (en) * | 1988-09-07 | 1990-04-27 | Lab De Hygiene & De Dietetique | Automatic adhesive apparatus for percutaneous administration of effective component |
JPH02288826A (en) * | 1989-01-20 | 1990-11-28 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Antitumor activ substance, especially skin treating system containing 5-fluorouracil |
JPH03193732A (en) * | 1989-11-29 | 1991-08-23 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Percutaneous medical system having buprenorphine as active substance |
JPH03204811A (en) * | 1989-10-06 | 1991-09-06 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Active plaster and its production |
JPH03111530U (en) * | 1990-02-27 | 1991-11-14 | ||
JPH0421521U (en) * | 1990-06-14 | 1992-02-24 | ||
JPH04230212A (en) * | 1990-06-25 | 1992-08-19 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Plaster high in content of softened internal substance |
JPH05500510A (en) * | 1989-09-08 | 1993-02-04 | シグナス インコーポレイテッド | Solid matrix system for transdermal drug delivery |
US5413776A (en) * | 1990-02-27 | 1995-05-09 | Sekisui Chemical Co., Ltd. | Pharmaceutical preparation for percutaneous absorption |
US5770219A (en) * | 1989-09-08 | 1998-06-23 | Cygnus Inc. | Solid matrix system for transdermal drug delivery |
US5783208A (en) * | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
US5916968A (en) * | 1996-01-17 | 1999-06-29 | National Starch And Chemical Investment Holding Corporation | Adhesives resistant to skin-penetration enhancers |
WO2005034925A1 (en) * | 2003-09-22 | 2005-04-21 | Hisamitsu Pharmaceutical Co., Inc. | Lowly irritative adhesive patch |
KR20220122627A (en) | 2019-12-27 | 2022-09-02 | 니찌방 가부시기가이샤 | tape |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5425537A (en) * | 1977-07-27 | 1979-02-26 | Soura Enajii Dainamitsukusu Co | Solar energy accumulator |
JPS56140927A (en) * | 1980-04-07 | 1981-11-04 | Nitto Electric Ind Co Ltd | Medical member |
JPS57139011A (en) * | 1981-02-20 | 1982-08-27 | Nitto Electric Ind Co Ltd | Material for releasing physiologically active substance |
-
1983
- 1983-12-07 JP JP23178283A patent/JPS60123417A/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5425537A (en) * | 1977-07-27 | 1979-02-26 | Soura Enajii Dainamitsukusu Co | Solar energy accumulator |
JPS56140927A (en) * | 1980-04-07 | 1981-11-04 | Nitto Electric Ind Co Ltd | Medical member |
JPS57139011A (en) * | 1981-02-20 | 1982-08-27 | Nitto Electric Ind Co Ltd | Material for releasing physiologically active substance |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02115119A (en) * | 1988-09-07 | 1990-04-27 | Lab De Hygiene & De Dietetique | Automatic adhesive apparatus for percutaneous administration of effective component |
JPH0784378B2 (en) * | 1989-01-20 | 1995-09-13 | エル テー エス ローマン テラピー・システーメ ゲー.エム.ベー.ハー ウント コンパニー カー.ゲー | Skin therapeutic agent having antitumor active substance |
JPH02288826A (en) * | 1989-01-20 | 1990-11-28 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Antitumor activ substance, especially skin treating system containing 5-fluorouracil |
US6149935A (en) * | 1989-09-08 | 2000-11-21 | Ortho-Mcneil Pharmaceutical, Inc. | Solid matrix system for transdermal drug delivery |
US5980932A (en) * | 1989-09-08 | 1999-11-09 | Cygnus, Inc. | Solid matrix system for transdermal drug delivery |
US5770219A (en) * | 1989-09-08 | 1998-06-23 | Cygnus Inc. | Solid matrix system for transdermal drug delivery |
JPH05500510A (en) * | 1989-09-08 | 1993-02-04 | シグナス インコーポレイテッド | Solid matrix system for transdermal drug delivery |
JPH03204811A (en) * | 1989-10-06 | 1991-09-06 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Active plaster and its production |
JPH03193732A (en) * | 1989-11-29 | 1991-08-23 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Percutaneous medical system having buprenorphine as active substance |
US5413776A (en) * | 1990-02-27 | 1995-05-09 | Sekisui Chemical Co., Ltd. | Pharmaceutical preparation for percutaneous absorption |
JPH03111530U (en) * | 1990-02-27 | 1991-11-14 | ||
JPH0421521U (en) * | 1990-06-14 | 1992-02-24 | ||
JPH04230212A (en) * | 1990-06-25 | 1992-08-19 | Lts Lohmann Therapie Syst Gmbh & Co Kg | Plaster high in content of softened internal substance |
US5916968A (en) * | 1996-01-17 | 1999-06-29 | National Starch And Chemical Investment Holding Corporation | Adhesives resistant to skin-penetration enhancers |
US5783208A (en) * | 1996-07-19 | 1998-07-21 | Theratech, Inc. | Transdermal drug delivery matrix for coadministering estradiol and another steroid |
WO2005034925A1 (en) * | 2003-09-22 | 2005-04-21 | Hisamitsu Pharmaceutical Co., Inc. | Lowly irritative adhesive patch |
KR20220122627A (en) | 2019-12-27 | 2022-09-02 | 니찌방 가부시기가이샤 | tape |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH05194201A (en) | Pressure-sensitive silicone adhesive composition for use in percutaneous drug administration apparatus and related medical appliance | |
JP2015108007A (en) | Transdermal therapeutic system with neutralized acrylic adhesive patch | |
JP2849950B2 (en) | Transdermal formulation | |
JPH09511229A (en) | Estradiol penetration enhancer | |
JPS60123417A (en) | Drug delivery member | |
US4954343A (en) | Dermal pharmaceutical preparations | |
JP2587365B2 (en) | Preparation of transdermal preparations | |
JP2931607B2 (en) | Liquid composition for topical application | |
JP4167834B2 (en) | Adhesive and patch preparation using the same | |
JPH0152362B2 (en) | ||
JP2688778B2 (en) | Patch for disease treatment | |
JPH0429927A (en) | Plaster | |
JPS6314685B2 (en) | ||
JPH046164B2 (en) | ||
JP3554573B2 (en) | Aspirin-containing transdermal preparation | |
JPS597689B2 (en) | pharmaceutical formulations | |
JPH11209271A (en) | Percutaneously absorptive preparation | |
JPS597687B2 (en) | medical parts | |
JPH1045571A (en) | Plaster | |
JPH0238569B2 (en) | ||
JP2565334B2 (en) | Drug release variable patch preparation | |
JPS61221120A (en) | Medical material for external use | |
JPS62263120A (en) | Plaster | |
JPS61221121A (en) | Tape preparation | |
JPH085806B2 (en) | Transdermal formulation |